Moderna, Inc.
MRNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | 0.05 | -0.28 | -0.01 |
| FCF Yield | -25.40% | -10.07% | 6.47% | 13.03% |
| EV / EBITDA | -4.36 | -11.06 | 7.04 | 7.13 |
| Quality | ||||
| ROIC | -32.43% | -32.84% | 38.93% | 77.53% |
| Gross Margin | 54.24% | 31.47% | 71.31% | 85.24% |
| Cash Conversion Ratio | 0.84 | 0.66 | 0.60 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -44.66% | -27.18% | 186.41% | 565.37% |
| Free Cash Flow Growth | -6.01% | -183.50% | -65.65% | 580.57% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 0.51 | -0.21 | -0.44 |
| Interest Coverage | -164.38 | -111.55 | 324.83 | 738.67 |
| Efficiency | ||||
| Inventory Turnover | 12.51 | 23.23 | 5.71 | 1.82 |
| Cash Conversion Cycle | -4.26 | 32.88 | 63.72 | 227.25 |